Preliminary results reported in this grant demonstrated that specific polypeptide doxorubicin conjugates showed increased cytoxicity and decreased toxicity when used in conjunction with hyperthermia. Specific targeting of the proposed chemotherapeutic polypeptide carriers to solid tumors by local hyperthermia is said to increase specificity and efficacy of treatment and reduce the toxicity to normal tissues. According to the company the research will be expanded to other drugs and animal testing to choose the best candidate to bring into clinical development.
Donald Picker, COO of Oncolin, said: “We are very happy that this program has received funding from such a prestigious organization as the NIH to help progress this potential platform technology.”